Dr. Garon on Immunotherapy as Salvage Treatment for Advanced Lung Cancer

Edward B. Garon, MD
Published: Friday, Nov 10, 2017



Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses the possibility of administering PD-1 or PD-L1 blockades as a third-line or salvage therapy for patients with advanced lung cancer.

While it is understood that these agents may work in the second-line setting for some patients, to date, researchers and clinicians are still unsure whether some patients would have more of a benefit holding a select treatment off until a later setting.

However, Garon mentioned that by examining data from recent clinical trials, researchers might be able to determine appropriate patients to receive PD-1/PD-L1 inhibitors as salvage therapy.

<<< View more from the 2017 Chemotherapy Foundation Symposium


Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses the possibility of administering PD-1 or PD-L1 blockades as a third-line or salvage therapy for patients with advanced lung cancer.

While it is understood that these agents may work in the second-line setting for some patients, to date, researchers and clinicians are still unsure whether some patients would have more of a benefit holding a select treatment off until a later setting.

However, Garon mentioned that by examining data from recent clinical trials, researchers might be able to determine appropriate patients to receive PD-1/PD-L1 inhibitors as salvage therapy.

<<< View more from the 2017 Chemotherapy Foundation Symposium

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x